Bolt Biotherapeutics (NASDAQ:BOLT) Stock Price Crosses Below 200 Day Moving Average – Here’s What Happened

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)’s stock price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $5.61 and traded as low as $4.75. Bolt Biotherapeutics shares last traded at $4.96, with a volume of 21,772 shares changing hands.

Analyst Ratings Changes

BOLT has been the subject of a number of research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Wednesday, October 8th. Zacks Research cut shares of Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Lake Street Capital boosted their price target on Bolt Biotherapeutics to $75.00 and gave the company a “buy” rating in a research note on Friday, August 15th. Finally, HC Wainwright set a $7.00 price target on Bolt Biotherapeutics and gave the company a “buy” rating in a report on Monday, October 20th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Bolt Biotherapeutics has an average rating of “Hold” and an average target price of $34.00.

Bolt Biotherapeutics Stock Performance

The firm has a market capitalization of $9.52 million, a price-to-earnings ratio of -0.22 and a beta of 0.93. The firm’s 50-day moving average price is $5.36 and its two-hundred day moving average price is $5.61. The company has a debt-to-equity ratio of 0.65, a quick ratio of 3.57 and a current ratio of 3.57.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($3.72) EPS for the quarter, topping analysts’ consensus estimates of ($5.07) by $1.35. The business had revenue of $2.17 million for the quarter, compared to the consensus estimate of $0.82 million. Sell-side analysts predict that Bolt Biotherapeutics, Inc. will post -1.61 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of BOLT. Squarepoint Ops LLC lifted its holdings in shares of Bolt Biotherapeutics by 19.8% during the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after acquiring an additional 2,448 shares during the period. Shay Capital LLC acquired a new stake in shares of Bolt Biotherapeutics during the 3rd quarter worth about $85,000. Finally, Susquehanna International Group LLP bought a new position in Bolt Biotherapeutics during the 3rd quarter valued at about $89,000. 86.70% of the stock is currently owned by institutional investors and hedge funds.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.